Fw: The relationship between simian virus 40 and mesothelioma.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:29 AM
Subject: The relationship between simian virus 40 and mesothelioma.

[1]Curr Opin Pulm Med. 2008 Jul; 14(4): 316-321
Rivera Z, Strianese O, Bertino P, Yang H, Pass H, Carbone M

PURPOSE OF REVIEW: Simian virus 40 is present in some human malignant mesotheliomas. The evidence in favor and against a pathogenic role of simian virus 40 in malignant mesothelioma is discussed in this review. RECENT FINDINGS: When simian virus 40 is injected intracardially into hamsters, 60% develop and die of malignant mesothelioma. Moreover, some human malignant mesotheliomas contain and express simian virus 40 DNA and proteins. To date, over 50 laboratories have detected simian virus 40 in malignant mesotheliomas and in other tumors; however, the variability of the percentage of positivity led to a controversy about the role and significance of simian virus 40 in malignant mesotheliomas. Compared with other cell types, human mesothelial cells are unusually susceptible to simian virus 40-induced malignant transformation. The presence of simian virus 40 in malignant mesothelioma has been associated with the activation of specific oncogene pathways. Cocarcinogenesis between simian virus 40 and asbestos in causing malignant mesotheliomas has been demonstrated in three separate research laboratories using different experimental approaches. Epidemiological data possibly linking simian virus 40 and malignant mesothelioma is lacking owing to unattainable identification of infected from noninfected cohorts. SUMMARY: Available evidence appears sufficient to link simian virus 40 either alone or in conjunction with asbestos in causing malignant mesotheliomas; however, it is still insufficient to speculate about the contribution of simian virus 40 to the overall incidence of malignant mesotheliomas.



___
Source: http://www.hubmed.org/display.cgi?uids=18520265
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Mesothelioma due to environmental exposure to erionite in Turkey.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:29 AM
Subject: Mesothelioma due to environmental exposure to erionite in Turkey.

[1]Curr Opin Pulm Med. 2008 Jul; 14(4): 322-5
Dikensoy O

PURPOSE OF REVIEW: The prevalence of malignant mesothelioma due to erionite exposure in Central Anatolia is very high. In this report, we review the recent developments on this epidemic on the basis of previous literature. RECENT FINDINGS: Recently, it has been shown that erionite is poorly cytotoxic, induces proliferating signals and high growth rate in human mesothelial cells. Additionally, long-term exposure to erionite transforms human mesothelial cells in vitro, regardless of the presence of Simian Virus 40 sequences, leading to foci formation in cultured monolayers. It has also been confirmed that a genetic predisposition to erionite carcinogenesis is the cause of the mesothelioma epidemic in Cappadocia. SUMMARY: The data obtained recently on the epidemiology, etiology, and pathogenesis of the mesothelioma due to erionite exposure in Turkey are described.



___
Source: http://www.hubmed.org/display.cgi?uids=18520266
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:29 AM
Subject: Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues.

[1]Curr Opin Pulm Med. 2008 Jul; 14(4): 326-30
Davies HE, Musk AW, Lee YG

PURPOSE OF REVIEW: Malignant mesothelioma is a uniformly fatal disease and active supportive care, minimizing patient morbidity, remains the accepted standard treatment. Tract metastases in patients with mesothelioma are a well recognized complication of pleural intervention and prophylactic radiotherapy is commonly implemented to prevent their occurrence. This review critically analyzes the published literature to establish the role of prophylactic radiotherapy to pleural puncture sites and highlights controversies that exist. RECENT FINDINGS: Current practice is based on a clinical study published in 1995. However, two recent randomized controlled trials did not support the widely held belief that all patients undergoing diagnostic or therapeutic pleural puncture should receive prophylactic drain site irradiation. Data assessing the incidence of associated morbidity from tract metastases suggest that rates are lower than previously thought. SUMMARY: The routine administration of radiotherapy in all patients with mesothelioma following pleural intervention remains debated. Instead of prophylactic irradiation, directing surveillance toward patients with large (e.g. thoracoscopic) pleural puncture sites and reserving treatments to symptomatic deposits may be more appropriate. This strategy would optimize patient care and minimize hospital visits, but allow prompt instigation of treatment if symptoms develop.



___
Source: http://www.hubmed.org/display.cgi?uids=18520267
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Image-guided pleural biopsy.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:29 AM
Subject: Image-guided pleural biopsy.

[1]Curr Opin Pulm Med. 2008 Jul; 14(4): 331-6
Rahman NM, Gleeson FV

PURPOSE OF REVIEW: Pleural diseases are a common and increasing clinical problem. Establishing accurate diagnosis is an essential step in management of these patients, and approximately 40% of pleural effusions will remain undiagnosed after initial diagnostic thoracocentesis. Obtaining pleural tissue (by blind, image-guided or thoracoscopic pleural biopsy) is therefore a key procedure. Recent evidence provides important information on the relative value of each of these techniques. RECENT FINDINGS: For the diagnosis of malignant pleural disease, both thoracoscopic and image-guided biopsy have a far higher diagnostic yield than blind pleural biopsy. Cutting needle biopsies have a higher diagnostic yield in malignancy (and especially mesothelioma) compared with fine needle aspiration. The complication rate of image-guided biopsy is low. Rates of biopsy site tract invasion by mesothelioma may be lower using smaller biopsy ports, as used for image-guided pleural biopsy. SUMMARY: Blind pleural biopsy should no longer be conducted for the study of malignant pleural disease if facilities for other techniques are available. Image-guided and thoracoscopic biopsies have similarly high diagnostic rates, and are complementary techniques used in different clinical situations. Further studies assessing biopsy tract site invasion from mesothelioma with different biopsy techniques are required.



___
Source: http://www.hubmed.org/display.cgi?uids=18520268
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Word of Mouse Issue 30

----- Forwarded Message ----
From: Search for mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, June 20, 2008 4:31:42 AM
Subject: Word of Mouse Issue 30

In his essay, The Median Isn't the Message , Stephen Jay Gould recalls that when he was first diagnosed with abdominal mesothelioma, a rare form of cancer, his consultant suggested that maybe he shouldn't read ...

Wed, 18 Jun 2008 09:52:50 GMT

___
Source: http://www.philosophersnet.com/magazine/article.php?id=851
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fw: [Chemotherapy of malignant pleural mesothelioma: have we made any progress?]

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Sunday, June 22, 2008 10:52:17 PM
Subject: [Chemotherapy of malignant pleural mesothelioma: have we made any progress?]

[1]Zentralbl Chir. 2008 Jun; 133(3): 238-42
Reck M, Heigener DF, Gatzemeier U

Chemotherapy of malignant mesothelioma is of great importance because most patients with malignant pleural mesothelioma are diagnosed for the first time with widespread or advanced disease. Due to the small number of patients in clinical trials and due to difficulties in tumour assessment in the last 20 years, validation criteria for efficacy could only be defined with major limitations. After the introduction of modern antifolates in the chemotherapy for malignant mesothelioma and after the establishment of standardised response criteria, a significant prolongation of survival time by combination chemotherapy was shown in two randomised phase III trials. The combination of pemetrexed and cisplatin is the current standard of chemotherapy in malignant mesothelioma. Besides first-line therapy, there are also data to support the efficacy of chemotherapy in pretreated patients. In spite of the various results of preclinical trials which support the prognostic significance of certain targeted structures of intra- and intercellular signal transduction, no relevant efficacy could be shown for targeted therapies in mesothelioma up to now.



___
Source: http://www.hubmed.org/display.cgi?uids=18563688
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: [Multimodal Therapy for Malignant Pleural Mesothelioma Including Extrapleural Pneumonectomy.]

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Sunday, June 22, 2008 10:52:17 PM
Subject: [Multimodal Therapy for Malignant Pleural Mesothelioma Including Extrapleural Pneumonectomy.]

[1]Zentralbl Chir. 2008 Jun; 133(3): 231-237
Sienel W, Kirschbaum A, Passlick B

Multimodal therapy including neoadjuvant chemotherapy with subsequent extrapleural pneumonectomy and postoperative radiotherapy has been shown to improve the survival of patients with malignant pleural mesothelioma (MPM) if they are selected carefully. Careful patient selection is required in order to administer aggressive multimodal therapy only to patients who will benefit from such a treatment. To achieve an accurate staging (

___
Source: http://www.hubmed.org/display.cgi?uids=18563687
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: [Mesothelioma: a still current occupational cancer]

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Sunday, June 22, 2008 10:52:17 PM
Subject: [Mesothelioma: a still current occupational cancer]

[1]Rev Med Liege. 2008 Mar; 63(3): 128-35
Corhay JL, Duysinx B, Louis R

Mesothelioma is a rare tumour, particularly aggressive, whose incidence increases because of the massive use of asbestos during the last century. Asbestos remains indeed the principal etiologic agent of this cancer. In the event of mesothelioma it is advisable to seek an exposure, even of short duration, often which dates back to several decades. In certain circumstances compensation can be obtained at the Occupational Diseases Found. The renewed interest with regard to this tumour is supported by the improvement of mesothelioma management, the new imaging techniques, the new treatments and the broad diffusion of information related to the risk of developing this tumour following asbestos inhalation.



___
Source: http://www.hubmed.org/display.cgi?uids=18561768
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc